CA2557625A1 - Method of treatment of systemic injury secondary to burns - Google Patents

Method of treatment of systemic injury secondary to burns Download PDF

Info

Publication number
CA2557625A1
CA2557625A1 CA002557625A CA2557625A CA2557625A1 CA 2557625 A1 CA2557625 A1 CA 2557625A1 CA 002557625 A CA002557625 A CA 002557625A CA 2557625 A CA2557625 A CA 2557625A CA 2557625 A1 CA2557625 A1 CA 2557625A1
Authority
CA
Canada
Prior art keywords
side chain
alkyl
aryl
amino acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002557625A
Other languages
English (en)
French (fr)
Inventor
Ian Alexander Shiels
Steven Maxwell Taylor
Shelli Z. Stocks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2557625A1 publication Critical patent/CA2557625A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
CA002557625A 2003-05-26 2004-05-26 Method of treatment of systemic injury secondary to burns Abandoned CA2557625A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003902586A AU2003902586A0 (en) 2003-05-26 2003-05-26 Treatment of burns
AU2003902586 2003-05-26
PCT/AU2004/000703 WO2004103392A1 (en) 2003-05-26 2004-05-26 Method of treatment of systemic injury secondary to burns

Publications (1)

Publication Number Publication Date
CA2557625A1 true CA2557625A1 (en) 2004-12-02

Family

ID=31953629

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002557625A Abandoned CA2557625A1 (en) 2003-05-26 2004-05-26 Method of treatment of systemic injury secondary to burns

Country Status (6)

Country Link
US (1) US20070054841A1 (enExample)
EP (1) EP1641482A1 (enExample)
JP (1) JP2006528209A (enExample)
AU (1) AU2003902586A0 (enExample)
CA (1) CA2557625A1 (enExample)
WO (1) WO2004103392A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
ATE509632T1 (de) * 2002-10-16 2011-06-15 Promics Pty Ltd Behandlung von entzündlicher darmerkrankung
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions

Also Published As

Publication number Publication date
US20070054841A1 (en) 2007-03-08
WO2004103392A1 (en) 2004-12-02
JP2006528209A (ja) 2006-12-14
EP1641482A1 (en) 2006-04-05
AU2003902586A0 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
JP2793719B2 (ja) サイトカイン抑制剤
JP2810240B2 (ja) サイトカイン調節剤およびサイトカインレベルの変化に関連する病状および状態における使用方法
KR101999756B1 (ko) Ｃｄ36 발현을 감소시키는 방법
KR101479148B1 (ko) 주형 고정된 펩타이드 모방체
US5786332A (en) Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US20080058252A1 (en) Use of C5A receptor antagonist in the treatment of fibrosis
US11154587B2 (en) Use of peptides to stimulate the immune system
WO2009151714A2 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
KR100701539B1 (ko) 멜라가트란의 신규 용도
CA2542507C (en) Treatment of inflammatory bowel disease
CA2557615A1 (en) Treatment of haemorrhagic shock using complement 5a receptor inhibitors
CN102946897B (zh) 糖尿病的血管并发症的治疗
US20070054841A1 (en) Method of treatment of systemic injury secondary to burns
AU2004241673A1 (en) Method of treatment of systemic injury secondary to burns
US20200254059A1 (en) Therapeutic agent of uremia containing alarin as the main ingredient
US20070021329A1 (en) Treatment of hypersensitivity conditions
CN114989246A (zh) Fk3多肽类似物及其应用
JPH09510688A (ja) Ｃｘｃインタークリン分子のペプチド阻害剤
KR101733564B1 (ko) 디케토피페라진을 유효성분으로 포함하는 전신염증질환의 예방 또는 치료용 약학적 조성물
AU2003215446B2 (en) Use of C5a receptor antagonist in the treatment of fibrosis
AU2003266862B2 (en) Treatment of hypersensitivity conditions
CN121574193A (zh) 基于fk3的碳硼烷偶联肽及其制备方法和应用
ES2366538T3 (es) Tratamiento de la enfermedad inflamatoria intestinal.
AU2003266862A1 (en) Treatment of hypersensitivity conditions

Legal Events

Date Code Title Description
FZDE Discontinued